Merck & Co Coverage Initiated by Analysts at Credit Suisse (MRK)
Investment analysts at Credit Suisse assumed coverage on shares of Merck & Co (NYSE:MRK) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock.
Shares of Merck & Co (NYSE:MRK) traded down 0.29% during mid-day trading on Tuesday, hitting $47.75. The stock had a trading volume of 14,026,898 shares. Merck & Co has a 1-year low of $40.02 and a 1-year high of $50.16. The stock’s 50-day moving average is $47.77 and its 200-day moving average is $47.24. The company has a market cap of $139.7 billion and a P/E ratio of 28.68.
Merck & Co (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was down 10.6% on a year-over-year basis. Analysts expect that Merck & Co will post $3.48 EPS for the current fiscal year.
A number of other firms have also recently commented on MRK. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Tuesday. Separately, analysts at Argus raised their price target on shares of Merck & Co from $52.00 to $54.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Merck & Co to $54.00 in a research note to investors on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $51.36.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.